Articles, insights, and posts about Child Development, early detection, and new methods in diagnosis and treatment.
NOTE: This post is based on a presentation made at the March 2018 ePharma conference in New York City. As with every element of the medical and scientific world, the pharmaceutical industry has nearly endless options for digital technology tools. The challenge becomes how to maximize those digital technologies during three critical stages: discovery, development, […]
The American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting 2018 Charlotte Convention Center · Charlotte, North Carolina · April 10-14, 2018 Charlotte, NC – The wait for ACMG is finally over! FDNA’s Face2Gene team is heading to Charlotte over the next few days and is growing anxious to share with you all that we have planned […]
FDNA’s CEO, Dekel Gelbman, joined two distinguished members of the genetics community—Dr. John Carey (University of Utah) and Dr. Christine Stanley (WuXi NextCODE)—on redefining phenotyping for clinical advancements and variant prioritization. Dr. Carey. a highly-practiced clinician, currently at the University of Utah’s Department of Medical Genetics, kicked off the webinar with a comprehensive background on […]
In its 44 year history, Greenwood Genetic Center (GGC) has seen over 80,000 patient cases. That’s a lot of data. And hiding in the mountains of information are insights sometimes invisible to the human eye, insights that artificial intelligence like the Face2Gene technologies can tease out from obscurity. At the Microsoft booth at HiMSS, Anthony […]
HIMSS Conference, Microsoft booth Thursday, March 7 3:40 PM PST Las Vegas, Nevada As over 40,000 health IT professionals, clinicians, executives, and vendors from around the world gather at this year’s HIMSS Annual Conference & Exhibition, speaker Anthony Antonuccio, VP of Product at FDNA shares FDNA’s experience with one of the leading clinics, Greenwood Genetic […]
Today is World Rare Disease Day 2018. At FDNA, we recognize that one day is simply not enough time to raise awareness for the plight of rare and undiagnosed patients. Their diseases impact their lives and the lives of their families every day. Their symptoms, their struggles, their fight for more awareness–both socially and in […]
English | Spanish In a packed auditorium at Mexico City’s CENTRO University, FDNA’s Senior Director of Marketing, Jeff Daniels, announced the launch of the Genomics Collaborative. This initiative prompts clinicians, patients, advocates and researchers to join forces in an effort to accelerate breakthroughs in precision medicine. The Genomics Collaborative allows participants to access FDNA’s deep […]
The National Institutes of Health (NIH) recently launched a program to accelerate the transition of genome editing into clinical applications. Over the next six years, this Somatic Cell Genome Editing program aims to award $190 million to researchers for projects focused on creating and improving gene editing tools and delivery systems, testing the efficacy and […]
At FDNA, we’re making precision medicine a reality by crowdsourcing knowledge and integrating next-generation phenotyping (NGP) technologies into every patient evaluation. NGP is the computational capture, analysis and integration of phenotypic data into health analysis—a hallmark of FDNA’s technologies. In 2017, our Face2Gene application turned five, and alongside our collaborators, we marked some serious milestones: […]